Showing 1 - 20 results of 56 for search 'M. V. Cherkasova', query time: 0.07s Refine Results
  1. 1
    Dynamics of the level of calprotectin in patients with rheumatoid arthritis during rituximab biosimilar (Acellbia “Biocad”) therapy

    Dynamics of the level of calprotectin in patients with rheumatoid arthritis during rituximab biosimilar (Acellbia “Biocad”) therapy by A. S. Avdeeva, M. V. Cherkasova, E. L. Nasonov

    Published 2021-09-01
    Get full text
    Article
  2. 2
    CLINICAL ASSOCIATIONS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS TYPE 2 RECEPTOR IN SYSTEMIC SCLEROSIS

    CLINICAL ASSOCIATIONS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS TYPE 2 RECEPTOR IN SYSTEMIC SCLEROSIS by R. T. Alekperov, L. P. Ananyeva, M. V. Cherkasova

    Published 2018-11-01
    Get full text
    Article
  3. 3
    Different clinical relevance of anti-citrullinated proteins antibodies in RA patients

    Different clinical relevance of anti-citrullinated proteins antibodies in RA patients by A. S. Avdeeva, M. V. Cherkasova, E. L. Nasonov

    Published 2022-05-01
    Get full text
    Article
  4. 4
    Perception of Russian Politics in Galicia in Diaries and Memoirs of World War I Participants

    Perception of Russian Politics in Galicia in Diaries and Memoirs of World War I Participants by Yu. A. Zherdeva, E. I. Sumburova, M. V. Cherkasova

    Published 2021-08-01
    Get full text
    Article
  5. 5
    Serum amyloid A as a marker of ankylosing spondylitis activity

    Serum amyloid A as a marker of ankylosing spondylitis activity by K. V. Sakharova, M. V. Cherkasova, Sh. F. Erdes

    Published 2021-12-01
    Get full text
    Article
  6. 6
    The diagnostic value of serum IgG4 for the diagnosis of IgG4-related disease: and is that so great?

    The diagnostic value of serum IgG4 for the diagnosis of IgG4-related disease: and is that so great? by E. V. Sokol, M. V. Cherkasova, A. V. Torgashina

    Published 2019-03-01
    Get full text
    Article
  7. 7
    Current methods for laboratory diagnosis of rheumatoid arthritis

    Current methods for laboratory diagnosis of rheumatoid arthritis by A A Novikov, E N Aleksandrova, M V Cherkasova, E L Nasonov, A A Novikov, E N Aleksandrova, M V Cherkasova, E L Nasonov

    Published 2010-02-01
    Get full text
    Article
  8. 8
    Anti-Mullerian hormone in systemic lupus erythematosus

    Anti-Mullerian hormone in systemic lupus erythematosus by Z. S. Alekberova, O. N. Egorova, R. G. Goloeva, M. V. Cherkasova

    Published 2021-02-01
    Get full text
    Article
  9. 9
    Dynamics of lymphocyte subpopulations, CD4+CD25+CD127- T regulatory cells in patients with rheumatoid arthritis during therapy with the rituximab biosimilar Acellbia

    Dynamics of lymphocyte subpopulations, CD4+CD25+CD127- T regulatory cells in patients with rheumatoid arthritis during therapy with the rituximab biosimilar Acellbia by A. S. Avdeeva, Yu. P. Rubtsov, M. V. Cherkasova, E. L. Nasonov

    Published 2020-05-01
    Get full text
    Article
  10. 10
    Extra criterial antiphospholipid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus (preliminary data)

    Extra criterial antiphospholipid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus (preliminary data) by F. A. Cheldieva, T. M. Reshetnyak, M. V. Cherkasova, A. M. Lila

    Published 2021-10-01
    Get full text
    Article
  11. 11
    Clinical significance of antibodies to the phosphatidylserine/prothrombin complex

    Clinical significance of antibodies to the phosphatidylserine/prothrombin complex by T. M. Reshetnyak, F. A. Cheldieva, M. V. Cherkasova, A. M. Lila

    Published 2022-05-01
    Get full text
    Article
  12. 12
    Time course of changes in the level of N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with rheumatoid arthritis during therapy with an interleukin-6 receptor inhibitor

    Time course of changes in the level of N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with rheumatoid arthritis during therapy with an interleukin-6 receptor inhi... by E. V. Gerasimova, T. V. Popkova, A. V. Martynova, M. V. Cherkasova, D. S. Novikova

    Published 2019-11-01
    Get full text
    Article
  13. 13
    Clinical significance of leptin in systemic lupus erythematosus

    Clinical significance of leptin in systemic lupus erythematosus by L. V. Kondratyeva, T. A. Panafidina, T. V. Popkova, Yu. N. Gorbunova, M. V. Cherkasova

    Published 2021-12-01
    Get full text
    Article
  14. 14
    Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland)

    Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche... by A. S. Avdeeva, A. S. Artyukhov, E. B. Dashinimaeva, M. V. Cherkasova, E. L. Nasonov

    Published 2019-03-01
    Get full text
    Article
  15. 15
    Insulin resistance and type 2 diabetes mellitus risk factors in systemic lupus erythematosus

    Insulin resistance and type 2 diabetes mellitus risk factors in systemic lupus erythematosus by L. V. Kondratyeva, T. V. Popkova, M. V. Cherkasova, A. M. Lila, E. L. Nasonov

    Published 2021-09-01
    Get full text
    Article
  16. 16
    IMMUNOLOGICAL EFFECTS OF A RITUXIMAB BIOSIMILAR (ACELBIA, BIOCAD) IN PATIENTS WITH RHEUMATOID ARTHRITIS

    IMMUNOLOGICAL EFFECTS OF A RITUXIMAB BIOSIMILAR (ACELBIA, BIOCAD) IN PATIENTS WITH RHEUMATOID ARTHRITIS by A. S. Avdeeva, M. V. Cherkasova, D. A. Kusevich, V. V. Rybakova, E. L. Nasonov

    Published 2018-11-01
    Get full text
    Article
  17. 17
    Association between a low baseline level of gene expression of energy metabolism in the blood and the development of clinical remission in response to tofacitinib therapy in patients with rheumatoid arthritis

    Association between a low baseline level of gene expression of energy metabolism in the blood and the development of clinical remission in response to tofacitinib therapy in patien... by E. V. Chetina, A. M. Satybaldyev, G. A. Markova, E. Yu. Samarkina, M. V. Cherkasova

    Published 2021-06-01
    Get full text
    Article
  18. 18
    Antibodies to domain I β2 -glycoprotein 1 in patients with antiphospholipid syndrome and systemic lupus erythematosus

    Antibodies to domain I β2 -glycoprotein 1 in patients with antiphospholipid syndrome and systemic lupus erythematosus by F. A. Cheldieva, T. M. Reshetnyak, M. V. Cherkasova, S. I. Glukhova, A. M. Lila, E. L. Nasonov

    Published 2022-07-01
    Get full text
    Article
  19. 19
    ROLE OF MATRIX METALLOPROTEINASE 3 IN PREDICTING THE EFFICIENCY OF THERAPY FOR EARLY RHEUMATOID ARTHRITIS: THE REMARCA TRIAL

    ROLE OF MATRIX METALLOPROTEINASE 3 IN PREDICTING THE EFFICIENCY OF THERAPY FOR EARLY RHEUMATOID ARTHRITIS: THE REMARCA TRIAL by A. S. Avdeeva, E. N. Aleksandrova, D. E. Karateev, E. L. Luchikhina, M. V. Cherkasova, E. L. Nasonov

    Published 2016-03-01
    Get full text
    Article
  20. 20
    Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis

    Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis by A S Avdeeva, E N Aleksandrova, A A Novikov, M V Cherkasova, E Iu Panasiuk, E L Nasonov

    Published 2013-05-01
    Get full text
    Article

Search Tools: